Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

BACKGROUND: This phase I dose-finding trial evaluated safety, efficacy and pharmacokinetics of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, combined with platinum doublets in patients with advanced non-small cell lung cancer (NSCLC) an...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Kozloff, M F, Martin, L P, Krzakowski, M, Samuel, T A, Rado, T A, Arriola, E, De Castro Carpeño, J, Herbst, R S, Tarazi, J, Kim, S, Rosbrook, B, Tortorici, M, Olszanski, A J, Cohen, R B
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2012
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3494447/
https://ncbi.nlm.nih.gov/pubmed/22990652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.406
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы